Core Viewpoint - The company Keren Biotechnology (06990.HK) announced that three of its products have been included in the National Medical Insurance Directory published by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security of China on December 7, 2025 [1] Group 1 - The three products included are: (1) ADC Sacituzumab Tirumotecan (sac-TMT, also known as SKB264/MK-2870, brand name: Jiatailai®), (2) Cetuximab N01 Injection (formerly A140, brand name: Datailai®), and (3) Tagitanlimab (also known as A167, brand name: Ketailai®) [1] - Notably, ADC Sacituzumab Tirumotecan has two indications that have been included in the National Medical Insurance Directory [1]